Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxycycline
Drug ID BADD_D00725
Description Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline [FDA label]. This drug is a second-generation tetracycline, exhibiting lesser toxicity than first-generation tetracyclines [A174034]. Doxycycline may be used to treat a wide range of bacterial infections, depending on the results of antibiotic susceptibility testing.
Indications and Usage Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria. A complete list of organisms is available in the FDA label and in the "indications" section of this drug entry [FDA label]. The following are some of the major infections that may be treated with doxycycline [FDA label]: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (ornithosis) caused by Chlamydia psittaci Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis Nongonococcal urethritis caused by Ureaplasma urealyticum Relapsing fever due to Borrelia recurrentis **A note regarding anti-microbial resistance** It is important to note that doxycycline is not the drug of choice in the treatment of any type of staphylococcal infection. Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracyclines. Therefore, tetracyclines such as doxycycline should not be used to treat streptococcal infections unless the microorganism has been demonstrated to be susceptible [FDA label].
Marketing Status approved; investigational; vet_approved
ATC Code A01AB22; J01AA02
DrugBank ID DB00254
KEGG ID D00307; D07876
MeSH ID D004318
PubChem ID 54671203
TTD Drug ID D0S0LZ
NDC Product Code 23155-134; 50268-280; 63187-712; 67296-1368; 67296-1762; 68180-651; 71205-135; 71205-616; 71335-2100; 71335-2109; 76420-562; 59929-631; 69988-0020; 23155-135; 27808-233; 49884-726; 51407-678; 63323-130; 65841-823; 66794-237; 68382-911; 69238-1100; 0527-1338; 70518-1378; 70710-1122; 70710-1123; 72789-047; 0713-0572; 11014-0092; 0069-0970; 23155-136; 63187-135; 63187-936; 63304-130; 63304-616; 64380-206; 67296-1858; 68071-2761; 68083-481; 68382-706; 69238-1501; 0527-1335; 71335-1988; 71610-220; 62332-249; 62332-250; 63304-173; 64380-205; 67296-1385; 68999-417; 0527-1537; 70518-3488; 70934-996; 72189-006; 43386-792; 50090-5984; 55700-723; 0299-3822; 63187-672; 64380-179; 65841-821; 68071-2617; 68382-910; 70518-0038; 70518-3729; 70934-808; 71335-0861; 23155-133; 50268-281; 60687-716; 63629-8212; 68382-782; 69238-1500; 70771-1122; 71335-9608; 0713-0570; 0713-0571; 55488-0200; 40032-790; 46708-250; 51655-350; 62135-417; 67296-1570; 67296-1688; 67457-437; 68071-2152; 68180-652; 70518-3365; 70771-1007; 70771-1008; 70771-1009; 70934-499; 71335-2096; 0143-9381; 49884-727; 51655-711; 55700-122; 61919-276; 63304-131; 63304-614; 63629-7751; 64380-207; 0404-9855; 68071-2750; 68071-4354; 68180-650; 68382-707; 70518-0213; 70771-1121; 71335-1479; 72266-237; 16714-644; 40032-791; 43386-791; 60219-1100; 60687-344; 60760-721; 64380-180; 64380-181; 65841-822; 70710-1121; 70771-1006; 72789-199; 72789-258; 50909-8106; 40032-792; 43386-790; 46708-249; 49884-305; 50090-4833; 53002-0673; 53002-0674; 63304-132; 63304-615; 64380-208; 66993-815; 67296-1025; 68084-743; 68180-657; 68308-668; 0527-1535; 70518-0187; 70710-1124; 71205-385; 72789-308; 47621-017; 55018-164; 50090-5983; 51407-387
UNII N12000U13O
Synonyms Doxycycline | Doxycycline Monohydrate | Vibramycin | Atridox | Doxycycline Phosphate (1:1) | BMY-28689 | BMY 28689 | BMY28689 | BU-3839T | BU 3839T | BU3839T | Doryx | Doxycycline Calcium Salt (1:2) | Doxycycline Hyclate | Doxycycline Hemiethanolate | Doxycycline Monohydrochloride, 6-epimer | Doxycycline Monohydrochloride, 6 epimer | Doxycycline Monohydrochloride, Dihydrate | Doxycycline Calcium | 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))- | Alpha-6-Deoxyoxytetracycline | Alpha 6 Deoxyoxytetracycline | Doxycycline-Chinoin | Doxycycline Chinoin | Hydramycin | Oracea | Periostat | Vibra-Tabs | Vibra Tabs | Vibramycin Novum | Vibravenos
Chemical Information
Molecular Formula C22H24N2O8
CAS Registry Number 564-25-0
SMILES CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Inflammation08.01.05.007; 10.02.01.089--Not Available
Decreased appetite08.01.09.028; 14.03.01.0050.000049%
Feeling of body temperature change08.01.09.012--Not Available
Ill-defined disorder08.01.03.049--Not Available
Adverse drug reaction08.06.01.009--Not Available
Drug intolerance08.06.01.0130.000113%Not Available
Psychotic disorder19.03.01.0020.000022%
Pigmentation disorder23.05.03.001--Not Available
Unevaluable event08.01.03.051--Not Available
Tooth fracture12.01.17.024; 07.09.05.008--Not Available
Erosive oesophagitis07.04.05.004--Not Available
Vulvovaginal mycotic infection21.14.02.004; 11.03.05.004--Not Available
Treatment failure08.06.01.0170.000049%Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.008--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.000049%
Acute kidney injury20.01.03.0160.000022%
Upper-airway cough syndrome22.12.03.036--
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000044%Not Available
Mouth swelling23.04.01.020; 10.01.05.020; 07.05.04.007--Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000022%
Gastric mucosal hypertrophy07.11.03.0060.000022%Not Available
Tracheal stenosis22.04.07.010--
Bacterial vulvovaginitis21.14.02.013; 11.02.01.052--Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.000113%Not Available
Fixed eruption08.01.06.025; 23.03.05.008; 10.01.01.0370.000022%Not Available
Gastrointestinal mucosal necrosis24.04.08.019; 07.15.01.0050.000022%Not Available
Heavy menstrual bleeding21.01.03.005--Not Available
Hyperaesthesia teeth07.09.06.005--Not Available
Idiopathic intracranial hypertension17.07.02.0110.000022%Not Available
Sensitive skin23.03.03.097--Not Available
The 9th Page    First    Pre   9 10    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene